**PTU-181**

**OPTIMISED RESPONSE PREDICTION IN OESOPHAEGASTRIC ADENOCARCINOMAS (OGA) WITH COMBINATION OF MOLECULAR BIOMARKERS, SERUM CELL DEATH MARKERS AND FDG-PET**

doi:10.1136/gutjnl-2012-302514c.181

1G Bain,* 1Collie-Duguid, 2G Murray, 4Gilbert, 2A Denison, 2McKiddie, 1Ahearn, 1Leeds, 1Phull, 2K Park, 1A Welch, 1L Schweiger, 3R D Petty, 1Aberdeen Royal Infirmary, Aberdeen, UK; 2University of Aberdeen, Aberdeen, UK

**Introduction** Predictive biomarkers (BM) for OGA would optimise treatment selection and avoid ineffective therapy. Metabolic response (MR) defined as >55% decrease in tumour FDG Standardised Uptake Value (SUV) between day 0 and day 14 after starting chemotherapy has a high negative predictive value (95%) for response, but limited positive predictive value (50%). Combining molecular BMs and serum cell death markers with FDG-PET may optimise response prediction. We used global gene expression profiling (GEP) and cell death ELISAs to identify molecular BMs and serum markers that combined with FDG-PET would improve predictive accuracy.

**Methods** 28 patients with locally advanced/metastatic OGA received platinum based chemotherapy (PBC). FDG-PET scans were at day 0 & 14 and GEP (Affymetrix ST1.0 Exon Genechips) on day 0 tumour biopsies. A tissue microarray comprising an independent set of 154 OGA who had surgery +/− neoadjuvant PBC was used with immunohistochemistry (IHC) for qualification of GEP results. Cytokeratin 18 (CK18) M30 (apoptosis) and M65 (apoptosis + necrosis) ELISAs (Peviva, Sweden) were used to assess cell death from serial serum samples during chemo. Radiological response was assessed after 3/4 cycles of PBC by RECISTv1.1.

**Results** We identified a gene expression signature (86 genes) that separated FDG-PET MR patients (>55% fall SUV day 0−14) into those that do and do not have a RECIST response. In cross validation this signature correctly predicted response in 14/14 metabolic responders (MRs). Pathway analysis on GEP data identified potential novel mechanisms of response including the Leptin pathway. Leptin mRNA was higher in FDG MRs who did not have a RECIST response compared to those that did (p=0.026). In the independent set high Leptin protein by IHC was associated with lack of histopathologic response to neoadjuvant PBC (n=64, p=0.007).

High Leptin expression also had a therapy independent prognostic effect with longer survival in the absence of histopathologic response or with no neoadjuvant PBC and in low Leptin patients poor survival was mitigated to a degree by neoadjuvant PBC. Serum CK18 M30 decreased from day 0−14 in MRs but in metabolic non-responders (MNRs) there was a smaller fall or a rise (p=0.021). Levels in MNRs did not change with subsequent chemo. In MRs levels continued to fall in RECIST responders but increased again in non-responders.

**Conclusion** Molecular biomarkers (Leptin in particular) and serum cell death markers combine with FDG-PET to optimise response prediction in OGA. Further investigation of this combined molecular, serum and imaging approach is warranted.

**Competing interests** None declared.

**PTU-182**

**PERCUTANEOUS RADILOGICAL GASTROSTOMY IN OESOPHAGEAL CANCER PATIENTS: A FEASIBLE AND SAFE ACCESS FOR NUTRITIONAL SUPPORT DURING MULTIMODAL THERAPY**

doi:10.1136/gutjnl-2012-302514c.182

1G Piessen,* 2W B Robb, 2N Briere, 2A Boschetto, 2O Ernst, 2C Mariette, 1Department of Digestive and Oncological Surgery, University Hospital Claude Huriez, Lille, France; 2Department of Digestive Radiology, University Hospital Claude Huriez, Lille, France

**Introduction** Percutaneous endoscopic gastrostomy is not widely used in malnourished oesophageal cancer (OC) patients because of concerns about feasibility in frequently obstructive tumours, suitability of the stomach as an oesophageal substitute, and potential for metastatic inoculation. A percutaneous radiological gastrostomy (PRG) could be an optimal alternative.

**Methods** Experience with PRG among 1205 consecutive patients presenting with OC from 2000 to 2010 in our department was retrospectively reviewed. PRG was proposed for malnourished patients for whom neoadjuvant chemoradiation was scheduled. PRG placement success rate and major (Dindo-Clavien>II) related complications were analysed. A matched cohort analysis was then constructed in patients who underwent oesophagectomy with gastoplasty (n=759) to evaluate the impact of PRG placement on suitability of the gastric pull-up and on postoperative course. From 76 selected patients with PRG (PRG group), 152 randomly selected controls without PRG (no PRG group) were matched 2:1 by gender, age, ASA grade, cTNM stage and neoadjuvant treatment delivery.

**Results** PRG placement was planned in 269 (22.3%) patients mainly with locally advanced OC (63.8%). PRG placement was feasible in 259 (96.3%) patients. 60-day PRG-related mortality and major morbidity rates were 0% and 3.8%, respectively. For resected patients with gastoplasty, the PRG and no PRG groups were comparable regarding perioperative characteristics except for malnutrition more frequent in the PRG group (p<0.001). At the time of operation, PRG takedown and site closure were uncomplicated and the use of the stomach was possible in all 76 patients. Despite higher malnutrition rate at presentation in the PRG group, overall and oesophageal surgery related morbidity rates were similar between the two groups (p=0.452).

**Conclusion** PRG is feasible, safe and useful in non-selected patients with OC and does not compromise the suitability of the stomach as an oesophageal substitute in patients deemed to be resectable.

**Competing interests** None declared.

**PTU-183**

**INEFFECTIVENESS OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN THE EVALUATION OF TUMOUR RESPONSE AFTER COMPLETION OF NEOADJUVANT CHEMORADIATION IN OESOPHAGEAL CANCER**

doi:10.1136/gutjnl-2012-302514c.183

1,2,3G Piessen,* 4W B Robb, 2,5A Duhamel, 2,5X Mirabel, 2,3,4G Hugo, 1,2,5C Mariette. 1Department of Digestive Surgery, Lille University Hospital, Lille, France; 2University of Lille − Nord de France, Lille, France; 3Inserm, UMR837, Jean-Pierre Aubert Research Center, Team 5, Lille, France; 4Department of Nuclear Medicine, Lille University Hospital, Lille, France; 5Department of Statistics, Lille University Hospital, Lille, France; 6Academic Radiotherapy Department, CLCC Oscar Lambret Comprehensive Cancer Center, Lille, France

**Introduction** After primary CRT, a non-invasive evaluation of the tumour response could help in the treatment decision to identify patients who may benefit from surgery. Whether FDG-PET provides clinically relevant information remains questionable. The objective of this prospective trial was to evaluate the role of 18F-Fluorodeoxyglucose-positron emission tomography (FDG-PET) in the assessment of tumour response after the completion of neoadjuvant chemoradiation (CRT) in patients with locally advanced resectable oesophageal cancer.

**Methods** Operable patients with locally advanced oesophageal cancer (clinically staged T3 N0-1 M0) were enrolled. The complete